Salvatore Striano

Salvatore Striano

Auto-generated profile, based on publicly available information

Salvatore Striano

Department of Neuroscience, Reproductive and Odontostomatological Sciences, Federico II University, 80131 Naples, Italy

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 August 2020 in Brain Sciences
Verified
Journal Article
Open access
PDF file
Antonietta CoppolaAntonietta Coppola
Antonietta Coppola
MIMarta Ianniciello
Marta Ianniciello
EVEbru N. Vanli-Yavuz
Ebru N. Vanli-Yavuz
Settimio RossiSettimio Rossi
Settimio Rossi
Francesca SimonelliFrancesca Simonelli
Francesca Simonelli
LBLeonilda Bilo
Leonilda Bilo
Background: Sialidosis is a rare autosomal recessive disease caused by NEU1 mutations, leading to neuraminidase deficiency and accumulation of sialic acid-containing oligosaccharides and glycopeptides into the tissues. Sialidosis is divided into two clinical entities, depending on residual enzyme activity, and can be distinguished according to age of onset, clinical features, and progression. Type 1 sialidosis is the milder, late-onset form, also known as non-dysmorphic sialidosis. It is commonly characterized by progressive myoclonus, ataxia, and a macular cherry-red spot. As a rare condition, the diagnosis is often only made after few years from onset, and the clinical management might prove difficult. Furthermore, the information in the literature on the long-term course is scarce. Case presentations: We describe a comprehensive clinical, neuroradiological, ophthalmological, and electrophysiological history of four unrelated patients affected by type 1 sialidosis. The long-term care and novel clinical and neuroradiological insights are discussed. Discussion and conclusions: We report the longest follow-up (up to 30 years) ever described in patients with type 1 sialidosis. During the course, we observed a high degree of motor and speech disability with preserved cognitive functions. Among the newest antiseizure medication, perampanel (PER) was proven to be effective in controlling myoclonus and tonic–clonic seizures, confirming it is a valid therapeutic option for these patients. Brain magnetic resonance imaging (MRI) disclosed new findings, including bilateral gliosis of cerebellar folia and of the occipital white matter. In addition, a newly reported variant (c.914G > A) is described.

28 February 2007 in Epilepsy & Behavior
Verified
Journal Article
Closed access
PDF file
Pasquale StrianoPasquale Striano
Pasquale Striano
NSNicola Specchio
Nicola Specchio
RBRoberta Biancheri
Roberta Biancheri
NCNatalia Cannelli
Natalia Cannelli
ASAlessandro Simonati
Alessandro Simonati
SSSalvatore Striano
Salvatore Striano

1 October 2017 in Seizure: European Journal of Epilepsy
Verified
Journal Article
Closed access
PBPia Bernardo
Pia Bernardo
GDGalletta Diana
Galletta Diana
Felice IasevoliFelice Iasevoli
Felice Iasevoli
LDLuigi D’aMbrosio
Luigi D’aMbrosio
STSerena Troisi
Serena Troisi
Antonietta CoppolaAntonietta Coppola
Antonietta Coppola

31 March 2010 in Brain and Development
Verified
Journal Article
Closed access
ACAntonietta Coppola
Antonietta Coppola
Pasquale StrianoPasquale Striano
Pasquale Striano
SGStefania Gimelli
Stefania Gimelli
CCClotilde Ciampa
Clotilde Ciampa
LSLia Santulli
Lia Santulli
FZFederico Zara
Federico Zara